Disruption of tubular Flcn expression as a mouse model for renal tumor induction

Jindong Chen, Dachuan Huang, Isabelle Rubera, Kunihiko Futami, Pengfei Wang, Peter Zickert, Sok Kean Khoo, Karl Dykema, Ping Zhao, David Petillo, Brian Cao, Zhongfa Zhang, Shuhui Si, Susan R. Schoen, Ximing J. Yang, Ming Zhou, Guang Qian Xiao, Guan Wu, Magnus Nordenskjöld, Michel TaucBart O. Williams, Kyle A. Furge, Bin Tean Teh

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

The study of kidney cancer pathogenesis and its treatment has been limited by the scarcity of genetically defined animal models. The FLCN gene that codes for the protein folliculin, mutated in Birt-Hogg-Dubé syndrome, presents a new target for mouse modeling of kidney cancer. Here we developed a kidney-specific knockout model by disrupting the mouse Flcn in the proximal tubules, thus avoiding homozygous embryonic lethality or neonatal mortality, and eliminating the requirement of loss of heterozygosity for tumorigenesis. This knockout develops renal cysts and early onset (6 months) of multiple histological subtypes of renal neoplasms featuring high tumor penetrance. Although the majority of the tumors were chromophobe renal cell carcinomas in affected mice under 1 year of age, papillary renal cell carcinomas predominated in the kidneys of older knockout mice. This renal neoplasia from cystic hyperplasia at 4 months to high-grade renal tumors by 16 months represented the progression of tumorigenesis. The mTOR and TGF-β signalings were upregulated in Flcn-deficient tumors, and these two activated pathways may synergetically cause renal tumorigenesis. Treatment of knockout mice with the mTOR inhibitor rapamycin for 10 months led to the suppression of tumor growth. Thus, our model recapitulates human Birt-Hogg-Dubé kidney tumorigenesis, provides a valuable tool for further study of Flcn-deficient renal tumorigenesis, and tests new drugs/approaches to their treatment.

Original languageEnglish (US)
Pages (from-to)1057-1069
Number of pages13
JournalKidney International
Volume88
Issue number5
DOIs
StatePublished - Nov 1 2015

Fingerprint

Kidney
Carcinogenesis
Kidney Neoplasms
Neoplasms
Renal Cell Carcinoma
Knockout Mice
Penetrance
Estrone
Loss of Heterozygosity
Infant Mortality
Sirolimus
Hyperplasia
Cysts
Therapeutics
Animal Models
Growth
Pharmaceutical Preparations
Proteins

Keywords

  • BHD
  • FLCN
  • Gene targeting
  • Kidney cancer
  • Mouse model
  • MTOR
  • RCC
  • TGF-β

ASJC Scopus subject areas

  • Nephrology

Cite this

Chen, J., Huang, D., Rubera, I., Futami, K., Wang, P., Zickert, P., ... Teh, B. T. (2015). Disruption of tubular Flcn expression as a mouse model for renal tumor induction. Kidney International, 88(5), 1057-1069. https://doi.org/10.1038/ki.2015.177

Disruption of tubular Flcn expression as a mouse model for renal tumor induction. / Chen, Jindong; Huang, Dachuan; Rubera, Isabelle; Futami, Kunihiko; Wang, Pengfei; Zickert, Peter; Khoo, Sok Kean; Dykema, Karl; Zhao, Ping; Petillo, David; Cao, Brian; Zhang, Zhongfa; Si, Shuhui; Schoen, Susan R.; Yang, Ximing J.; Zhou, Ming; Xiao, Guang Qian; Wu, Guan; Nordenskjöld, Magnus; Tauc, Michel; Williams, Bart O.; Furge, Kyle A.; Teh, Bin Tean.

In: Kidney International, Vol. 88, No. 5, 01.11.2015, p. 1057-1069.

Research output: Contribution to journalArticle

Chen, J, Huang, D, Rubera, I, Futami, K, Wang, P, Zickert, P, Khoo, SK, Dykema, K, Zhao, P, Petillo, D, Cao, B, Zhang, Z, Si, S, Schoen, SR, Yang, XJ, Zhou, M, Xiao, GQ, Wu, G, Nordenskjöld, M, Tauc, M, Williams, BO, Furge, KA & Teh, BT 2015, 'Disruption of tubular Flcn expression as a mouse model for renal tumor induction', Kidney International, vol. 88, no. 5, pp. 1057-1069. https://doi.org/10.1038/ki.2015.177
Chen J, Huang D, Rubera I, Futami K, Wang P, Zickert P et al. Disruption of tubular Flcn expression as a mouse model for renal tumor induction. Kidney International. 2015 Nov 1;88(5):1057-1069. https://doi.org/10.1038/ki.2015.177
Chen, Jindong ; Huang, Dachuan ; Rubera, Isabelle ; Futami, Kunihiko ; Wang, Pengfei ; Zickert, Peter ; Khoo, Sok Kean ; Dykema, Karl ; Zhao, Ping ; Petillo, David ; Cao, Brian ; Zhang, Zhongfa ; Si, Shuhui ; Schoen, Susan R. ; Yang, Ximing J. ; Zhou, Ming ; Xiao, Guang Qian ; Wu, Guan ; Nordenskjöld, Magnus ; Tauc, Michel ; Williams, Bart O. ; Furge, Kyle A. ; Teh, Bin Tean. / Disruption of tubular Flcn expression as a mouse model for renal tumor induction. In: Kidney International. 2015 ; Vol. 88, No. 5. pp. 1057-1069.
@article{4dbbcb01046e41c3896102bf25b14cf0,
title = "Disruption of tubular Flcn expression as a mouse model for renal tumor induction",
abstract = "The study of kidney cancer pathogenesis and its treatment has been limited by the scarcity of genetically defined animal models. The FLCN gene that codes for the protein folliculin, mutated in Birt-Hogg-Dub{\'e} syndrome, presents a new target for mouse modeling of kidney cancer. Here we developed a kidney-specific knockout model by disrupting the mouse Flcn in the proximal tubules, thus avoiding homozygous embryonic lethality or neonatal mortality, and eliminating the requirement of loss of heterozygosity for tumorigenesis. This knockout develops renal cysts and early onset (6 months) of multiple histological subtypes of renal neoplasms featuring high tumor penetrance. Although the majority of the tumors were chromophobe renal cell carcinomas in affected mice under 1 year of age, papillary renal cell carcinomas predominated in the kidneys of older knockout mice. This renal neoplasia from cystic hyperplasia at 4 months to high-grade renal tumors by 16 months represented the progression of tumorigenesis. The mTOR and TGF-β signalings were upregulated in Flcn-deficient tumors, and these two activated pathways may synergetically cause renal tumorigenesis. Treatment of knockout mice with the mTOR inhibitor rapamycin for 10 months led to the suppression of tumor growth. Thus, our model recapitulates human Birt-Hogg-Dub{\'e} kidney tumorigenesis, provides a valuable tool for further study of Flcn-deficient renal tumorigenesis, and tests new drugs/approaches to their treatment.",
keywords = "BHD, FLCN, Gene targeting, Kidney cancer, Mouse model, MTOR, RCC, TGF-β",
author = "Jindong Chen and Dachuan Huang and Isabelle Rubera and Kunihiko Futami and Pengfei Wang and Peter Zickert and Khoo, {Sok Kean} and Karl Dykema and Ping Zhao and David Petillo and Brian Cao and Zhongfa Zhang and Shuhui Si and Schoen, {Susan R.} and Yang, {Ximing J.} and Ming Zhou and Xiao, {Guang Qian} and Guan Wu and Magnus Nordenskj{\"o}ld and Michel Tauc and Williams, {Bart O.} and Furge, {Kyle A.} and Teh, {Bin Tean}",
year = "2015",
month = "11",
day = "1",
doi = "10.1038/ki.2015.177",
language = "English (US)",
volume = "88",
pages = "1057--1069",
journal = "Kidney International",
issn = "0085-2538",
publisher = "Nature Publishing Group",
number = "5",

}

TY - JOUR

T1 - Disruption of tubular Flcn expression as a mouse model for renal tumor induction

AU - Chen, Jindong

AU - Huang, Dachuan

AU - Rubera, Isabelle

AU - Futami, Kunihiko

AU - Wang, Pengfei

AU - Zickert, Peter

AU - Khoo, Sok Kean

AU - Dykema, Karl

AU - Zhao, Ping

AU - Petillo, David

AU - Cao, Brian

AU - Zhang, Zhongfa

AU - Si, Shuhui

AU - Schoen, Susan R.

AU - Yang, Ximing J.

AU - Zhou, Ming

AU - Xiao, Guang Qian

AU - Wu, Guan

AU - Nordenskjöld, Magnus

AU - Tauc, Michel

AU - Williams, Bart O.

AU - Furge, Kyle A.

AU - Teh, Bin Tean

PY - 2015/11/1

Y1 - 2015/11/1

N2 - The study of kidney cancer pathogenesis and its treatment has been limited by the scarcity of genetically defined animal models. The FLCN gene that codes for the protein folliculin, mutated in Birt-Hogg-Dubé syndrome, presents a new target for mouse modeling of kidney cancer. Here we developed a kidney-specific knockout model by disrupting the mouse Flcn in the proximal tubules, thus avoiding homozygous embryonic lethality or neonatal mortality, and eliminating the requirement of loss of heterozygosity for tumorigenesis. This knockout develops renal cysts and early onset (6 months) of multiple histological subtypes of renal neoplasms featuring high tumor penetrance. Although the majority of the tumors were chromophobe renal cell carcinomas in affected mice under 1 year of age, papillary renal cell carcinomas predominated in the kidneys of older knockout mice. This renal neoplasia from cystic hyperplasia at 4 months to high-grade renal tumors by 16 months represented the progression of tumorigenesis. The mTOR and TGF-β signalings were upregulated in Flcn-deficient tumors, and these two activated pathways may synergetically cause renal tumorigenesis. Treatment of knockout mice with the mTOR inhibitor rapamycin for 10 months led to the suppression of tumor growth. Thus, our model recapitulates human Birt-Hogg-Dubé kidney tumorigenesis, provides a valuable tool for further study of Flcn-deficient renal tumorigenesis, and tests new drugs/approaches to their treatment.

AB - The study of kidney cancer pathogenesis and its treatment has been limited by the scarcity of genetically defined animal models. The FLCN gene that codes for the protein folliculin, mutated in Birt-Hogg-Dubé syndrome, presents a new target for mouse modeling of kidney cancer. Here we developed a kidney-specific knockout model by disrupting the mouse Flcn in the proximal tubules, thus avoiding homozygous embryonic lethality or neonatal mortality, and eliminating the requirement of loss of heterozygosity for tumorigenesis. This knockout develops renal cysts and early onset (6 months) of multiple histological subtypes of renal neoplasms featuring high tumor penetrance. Although the majority of the tumors were chromophobe renal cell carcinomas in affected mice under 1 year of age, papillary renal cell carcinomas predominated in the kidneys of older knockout mice. This renal neoplasia from cystic hyperplasia at 4 months to high-grade renal tumors by 16 months represented the progression of tumorigenesis. The mTOR and TGF-β signalings were upregulated in Flcn-deficient tumors, and these two activated pathways may synergetically cause renal tumorigenesis. Treatment of knockout mice with the mTOR inhibitor rapamycin for 10 months led to the suppression of tumor growth. Thus, our model recapitulates human Birt-Hogg-Dubé kidney tumorigenesis, provides a valuable tool for further study of Flcn-deficient renal tumorigenesis, and tests new drugs/approaches to their treatment.

KW - BHD

KW - FLCN

KW - Gene targeting

KW - Kidney cancer

KW - Mouse model

KW - MTOR

KW - RCC

KW - TGF-β

UR - http://www.scopus.com/inward/record.url?scp=84947616797&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84947616797&partnerID=8YFLogxK

U2 - 10.1038/ki.2015.177

DO - 10.1038/ki.2015.177

M3 - Article

C2 - 26083655

AN - SCOPUS:84947616797

VL - 88

SP - 1057

EP - 1069

JO - Kidney International

JF - Kidney International

SN - 0085-2538

IS - 5

ER -